Oncology Deal Benchmarks
Licensing deals, acquisitions, and collaborations in solid tumors and hematologic malignancies. Benchmarks derived from 963 verified transactions.
963
Total Deals
$911M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
217
license
198
acquisition
202
collaboration
183
option
159
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
QIMR Berghofer → Kazia Therapeutics MSETC | license | $1M | — | Apr 2026 |
Telix Pharmaceuticals Limited → Regeneron Pharmaceuticals, Inc. | collaboration | $40M | $2.1B | Apr 2026 |
Tubulis → Gilead Sciences TUB-040 | acquisition | $3.1B | $5.0B | Apr 2026 |
Insilico Medicine → Eli Lilly AI-developed oral therapeutics (multiple preclinical programs) | license | $115M | $2.8B | Mar 2026 |
Synnovation Therapeutics → Novartis SNV4818 | acquisition | $2.0B | $3.0B | Mar 2026 |
Pikavation Therapeutics → Novartis SNV4818 | acquisition | $2.0B | $3.0B | Mar 2026 |
CytomX Therapeutics → Astellas Pharma | collaboration | $80M | $1.7B | Mar 2026 |
3SBio → Pfizer SSGJ-707 / PF-08634404 | license | $1.3B | $6.0B | Mar 2026 |
Sino Biopharmaceutical (Chia Tai Tianqing Pharmaceutical) → Sanofi rovadicitinib | license | $135M | $1.5B | Mar 2026 |
Vir Biotechnology → Astellas VIR-5500 | collaboration | $335M | $1.7B | Mar 2026 |
Benchmark Your Oncology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 963 verified oncology transactions.
Run Oncology Benchmark